Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care June 2007	Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006.
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
Managed Care April 2001	Employers easing prescription limitations? Some older medications once viewed by employers as "lifestyle" drugs when making benefit decisions are slowly gaining recognition as important components of primary care...
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
Managed Care May 2007 Rachel M. Renshaw	Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen.
The Motley Fool October 22, 2008 Brian Orelli	Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
Nutra Solutions April 1, 2005	Herbal Extract Shows Benefits for Diabetes Salacia oblonga, an herb used in traditional Indian medicine, may control the rise in blood sugar that follows a meal, thus helping to treat or possibly prevent type 2 diabetes.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
Managed Care February 2004	Improving Oral Pharmacologic Treatment And Management of Type 2 Diabetes New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
Managed Care October 2000	Diabetes Cases Up 33 Percent In Just 8 Years In findings that are likely to have serious implications for treatment-costs, adult incidence of diabetes rose 33 percent from 1990 to 1998, according to the U.S. Centers for Disease Control...
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
Managed Care June 2006	More Young Adults Prescribed ADHD Drugs The number of adults ages 20 to 44 prescribed attention deficit hyperactivity disorder medications increased about 140% from 2000 to 2005. This was even faster growth than the 82% reported for children.
The Motley Fool August 15, 2007 Billy Fisher	Adversity Continues for Avandia Avandia and Actos receive black box labels from the FDA. The two diabetes medications have been linked to an increase in heart failure.
AskMen.com April 29, 2001 Joshua Levine	Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease...
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
Managed Care October 2004 Martin Sipkoff	Not So Much of a Reach: Let Sick Pay Less for Drugs The idea is radical and simple: Those who need medication the most should pay the least. There is evidence that this is cost-effective.
The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool September 30, 2009 Brian Orelli	Less Is More for Novartis That makes it simple enough.
Managed Care July 2004 Udaya M. Kabadi	Cost-Effective Management of Hyperglycemia in Patients with Type 2 Diabetes Using Oral Agents Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
Managed Care January 2008	Copayment Rates Outpace Inflation Workers are definitely paying more for health benefits today than they were in 2000, especially for prescription drug copayments.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
Reason February 2009 Ronald Bailey	I Want a New Drug States that adopted new drugs more rapidly, had the smallest increases in disability rates.
BusinessWeek December 10, 2009 Weintraub & Wechsler	The New Prominence of Comparative Drug Trials Pharmaceutical makers, once wary of head-to-head trials, now embrace them as marketing tools.
The Motley Fool September 9, 2008 Brian Orelli	Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment.
American Family Physician November 1, 2000	Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations...
Managed Care April 2005	Diabetes Costs Rise, But so Does Adherence A typical health plan can expect endocrine and diabetes agents to amount to 6% to 8% of total utilization costs, with spending on these agents to increase between 11% and 15% 2005.
Nursing Management January 2012 Lawrence et al.	Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.
Managed Care August 2004 Martin Sipkoff	Bad Tiered Formulary Designs Yield Poor Outcomes, High Cost Now that tiered formularies rule the land, what many suspected is being demonstrated: Compliance is suffering and so, too, are patients.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
Pharmaceutical Executive April 1, 2006 Humphrey Taylor	Opinion: Unintended Outcomes for Consumer-Drive Insurance So-called "consumer-driven" health insurance is designed to help informed consumers make better decisions about their medical treatment. But the high deductibles associated with these plans are affecting the end goal.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
BusinessWeek April 30, 2010 Drew Armstrong	The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
Pharmaceutical Executive July 30, 2007 Peter Pitts	Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy.
Managed Care May 2006 Fadia T. Shaya & Deshpande	New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements.
The Motley Fool April 17, 2009 Brian Orelli	Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half.
The Motley Fool January 26, 2005 Stephen D. Simpson	Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through.
Managed Care May 2006 Martin Sipkoff	Health Plans Are Ill-Prepared for Looming Diabetes Epidemic The problem is outpacing insurers' resources and perhaps even their commitment. Can the chronic care model help?
Nutra Solutions September 1, 2005	Dairy Dupes Diabetes Researchers examined the relation between dairy intake and incident cases of type 2 diabetes in 41,254 male participants with no history of diabetes, cardiovascular disease, and cancer at baseline in the Health Professionals Follow-up Study.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 8, 2009 Brian Orelli	For the RECORD... Avandia's not going to make a comeback for GlaxoSmithKline.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.